MicroRNAs as Biomarkers for Obstructive Sleep Apnea
ConditionObstructive Sleep Apnea
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorUniversity of Pennsylvania
About this trial
Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients. This project will study microRNAs in order to develop and validate blood biomarkers that are specific to OSA, useful for identification of cases with OSA, reflective of efficacy of therapy, and able to predict blood pressure response to treatment of OSA.
Eligibility criteria
Qualifiers
age 18-75 years
moderate-severe OSA (defined as AHI ≥15 events/hour)
willing to accept PAP therapy
age 18-75 years
Disqualifiers
current use of PAP or other OSA treatments
home oxygen therapy
recent changes (within 3 months) to BP medications among those who are on these medications
presence of Cheyne-Stokes Respiration (CSR) in sleep study
Trial design
Treatments tested in this trial
- Positive Airway Pressure
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Pennsylvania
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov